Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Comparing the Risk of Thrombotic Events in Older Persons with Hemophilia a on Emicizumab Prophylaxis to Non-Emicizumab Products: A Single Center Observational Cohort Study

Shalini Vemuru, Stacey Fedewa, Christine L Kempton

Blood (2024) 144 (Supplement 1): 130.

https://doi.org/10.1182/blood-2024-202001

Published: 2024

Journal Articles

Sex-Differences in Distress, Quality of Life, and Depression Among People with Hemophilia

Sara Guasch Parks, Stacey Fedewa, Tyler Buckner, Ana G Antun, Lorraine Cafuir, Duc Q Tran, Jr., Shanna Mattis, Christine L Kempton

Blood (2022) 140 (Supplement 1): 8005–8007.

https://doi.org/10.1182/blood-2022-155967

Published: 2022

Journal Articles

Characteristics Associated with Receipt of Immune Tolerance Induction Among Patients with Severe Hemophilia a in the United States in the Pre-Emicizumab Era

Christine L Kempton, Stacey Fedewa, Amanda B Payne

Blood (2022) 140 (Supplement 1): 10752–10754.

https://doi.org/10.1182/blood-2022-155966

Published: 2022

Journal Articles

Racial/Ethnic Disparities in Hemophilia-Related Distress

Stacey Fedewa, Tyler Buckner, Duc Q Tran, Jr., Lorraine Cafuir, Ana G Antun, Shanna Mattis, Christine L Kempton

Blood (2022) 140 (Supplement 1): 1232–1233.

https://doi.org/10.1182/blood-2022-155968

Published: 2022

Journal Articles

Prophylaxis in hemophilia: how much is enough?

Christine L. Kempton

Blood (2021) 137 (13): 1709–1711.

https://doi.org/10.1182/blood.2020009603

Published: 2021

Journal Articles

Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B

Tyler W. Buckner, MDMSc, Shannon L Carpenter, MD, Stacy E. Croteau, MD, Adam Cuker, MDMS, Nabil Daoud, MA, Christine L Kempton, MDMSc, Lynn M Malec, MD, Thomas W. McLean, MD, Leslie J. Raffini, MD, Janice M Staber, MD, Michael Wang, MD, Crystal Watson, BS, Ayesha Zia, MD, Michael Recht, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137696

Published: 2020

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia Α Patients in the United States

Ming Y. Lim, MBBChir,MA, Dunlei Cheng, PhD, Christine L. Kempton, MD MSc, Nigel S. Key, MBChB, FRCP

Blood (2019) 134 (Supplement_1): 902.

https://doi.org/10.1182/blood-2019-122991

Published: 2019

Journal Articles

Validation of Instrument to Assess Hemophilia-Related Distress

Christine L. Kempton, MD MSc, Vaughn Barry, PhD MPH, Tyler W. Buckner, MD MSc, Janet Figueroa, MPH, Shanna Mattis, MPH, Mary Ellen Lynch, PhD, Mary E Stout, MD, Stephanie Whitten, Scott Gillespie, Courtney McCracken, PhD

Blood (2019) 134 (Supplement_1): 936.

https://doi.org/10.1182/blood-2019-122544

Published: 2019

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study

Blood (2018) 132 (Supplement 1): 2479.

https://doi.org/10.1182/blood-2018-99-119637

Published: 2018

Journal Articles

Epidemiology of Inhibitors in Persons with Severe Hemophilia a in the United States: Analyses of a National Database

Christopher M Sande, BSc, Amanda B Payne, MPH, PhD, Christine L Kempton, MD MSc, Marilyn J Manco-Johnson, MD, Anjali Sharathkumar, MBBS, MDMS

Blood (2018) 132 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2018-99-109978

Published: 2018

Journal Articles

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Lorraine Cafuir, MD, En Cheng, Christine L Kempton, MD MSc

Blood (2018) 132 (Supplement 1): 826.

https://doi.org/10.1182/blood-2018-99-110685

Published: 2018

Journal Articles

An Evaluation of Promis Health Domains in Adults with Hemophilia: A Cross-Sectional Study

Vaughn Barry, PhD MPH, Tyler W. Buckner, MD MSc, Shanna Mattis, MPH, Mary E Stout, MD, Christine L. Kempton

Blood (2018) 132 (Supplement 1): 493.

https://doi.org/10.1182/blood-2018-99-117216

Published: 2018

Journal Articles

Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study

Blood (2017) 130 (Supplement 1): 2359.

https://doi.org/10.1182/blood.V130.Suppl_1.2359.2359

Published: 2017

Journal Articles

HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a

Christine L Kempton, Amanda B. Payne, MPH

Blood (2017) 130 (Supplement 1): 177.

https://doi.org/10.1182/blood.V130.Suppl_1.177.177

Published: 2017

Journal Articles

Factor V Atlanta: A Novel Mutation in the F5 Gene Reveals Potential New Cis-Acting Elements Involved in Regulating FV-Short and TFPI Levels

Karen L Zimowski, MD, Michelle D. Ho, BS, Jordan E Shields, MS, Gabriela Denning, PhD, Teodolinda Petrillo, PhD, Navdeep Jhita, MD, Angel A Rivera, PhD, Miguel A Escobar, MD, Christine L Kempton, Christopher B Doering, PhD, Rodney M Camire, PhD

Blood (2017) 130 (Supplement 1): 366.

https://doi.org/10.1182/blood.V130.Suppl_1.366.366

Published: 2017

Journal Articles

Mortality Trends and Causes of Death in Persons with Hemophilia in the United States, 1999-2014

Amanda B. Payne, MPH, Nafisa Ghaji, MD, Jason M. Mehal, MSPH, Christina Chapman, MSPH, Dana L. Haberling, MSPH, Christine L Kempton, Christopher J. Bean, PhD, John Michael Soucie, PhD, William C. Hooper, PhD

Blood (2017) 130 (Supplement 1): 755.

https://doi.org/10.1182/blood.V130.Suppl_1.755.755

Published: 2017

Journal Articles

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse-Jarres, Christine L Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, MDPhD, Guy Young, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 1071.

https://doi.org/10.1182/blood.V130.Suppl_1.1071.1071

Published: 2017

Journal Articles

Characteristics of Males with Hemophilia in the United States Hemophilia Treatment Center Network (USHTCN) with New-Onset Elevated Inhibitor Titers, December 15, 2013 - December 31, 2016

Marilyn J Manco-Johnson, MD, J. Michael Soucie, PhD, Anjali Sharathkumar, MBBS, MDMS, Fiona Bethea, MPH, Christine L Kempton, Amanda B. Payne, MPH, Michael Wang, MD, Connie H Miller, PhD

Blood (2017) 130 (Supplement 1): 3408.

https://doi.org/10.1182/blood.V130.Suppl_1.3408.3408

Published: 2017

NARROW

Comparing the Risk of Thrombotic Events in Older Persons with Hemophilia a on Emicizumab Prophylaxis to Non-Emicizumab Products: A Single Center Observational Cohort Study

Sex-Differences in Distress, Quality of Life, and Depression Among People with Hemophilia

Characteristics Associated with Receipt of Immune Tolerance Induction Among Patients with Severe Hemophilia a in the United States in the Pre-Emicizumab Era

Racial/Ethnic Disparities in Hemophilia-Related Distress

Prophylaxis in hemophilia: how much is enough?

Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia Α Patients in the United States

Validation of Instrument to Assess Hemophilia-Related Distress

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study

Epidemiology of Inhibitors in Persons with Severe Hemophilia a in the United States: Analyses of a National Database

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

An Evaluation of Promis Health Domains in Adults with Hemophilia: A Cross-Sectional Study

Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study

HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a

Factor V Atlanta: A Novel Mutation in the F5 Gene Reveals Potential New Cis-Acting Elements Involved in Regulating FV-Short and TFPI Levels

Mortality Trends and Causes of Death in Persons with Hemophilia in the United States, 1999-2014

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Characteristics of Males with Hemophilia in the United States Hemophilia Treatment Center Network (USHTCN) with New-Onset Elevated Inhibitor Titers, December 15, 2013 - December 31, 2016

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only